Cargando…

Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer

BACKGROUND: In the present study, we aimed to investigate the expression and prognostic value of co-stimulatory molecules, programmed death ligand-1 (PD-L1) and PD-L2, in ovarian cancer (OC). METHODS: Immunohistochemical (IHC) staining was used to assess the expressions of PD-L1 and PD-L2 in 77 case...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xue, Chunyan, Zhu, Dawei, Chen, Lujun, Xu, Yun, Xu, Bin, Zhang, Dachuan, Jiang, Jingting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797717/ https://www.ncbi.nlm.nih.gov/pubmed/35116740 http://dx.doi.org/10.21037/tcr.2019.01.09

Ejemplares similares

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
por: Jiang, Siqing, et al.
Publicado: (2022)

Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2021)

Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors
por: Fan, Yangwei, et al.
Publicado: (2016)

Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
por: Zhu, Jun, et al.
Publicado: (2017)

Simultaneous high PD-L1 and low VEGFR2 expression is associated with better overall survival in rectal cancer
por: Ding, Yun, et al.
Publicado: (2021)

Prognostic value of PD –L1 expression in patients with primary solid tumors
por: Xiang, Xiao, et al.
Publicado: (2017)

The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis
por: Xu, Gang, et al.
Publicado: (2019)

Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours
por: Rösner, Erik, et al.
Publicado: (2021)

Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer
por: Zhang, Dachuan, et al.
Publicado: (2019)

The Prognostic and Therapeutic Value of PD-L1 in Glioma
por: Chen, Ruo Qiao, et al.
Publicado: (2019)

The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
por: Chen, Li, et al.
Publicado: (2022)

Prognostic and Clinical Value of Interleukin 6 and CD45(+)CD14(+) Inflammatory Cells with PD-L1(+)/PD-L2(+) Expression in Patients with Different Manifestation of Ovarian Cancer
por: Wertel, Iwona, et al.
Publicado: (2020)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
por: Zhu, Xinxin, et al.
Publicado: (2017)

The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis
por: Chen, Xiao-Jiang, et al.
Publicado: (2020)

The co-expression of CBX8 and PD-L1 and prognostic value in cervical cancer
por: Zhou, Hui, et al.
Publicado: (2021)

CD247 expression is associated with differentiation and classification in ovarian cancer
por: Ye, Wenfeng, et al.
Publicado: (2019)

Platelets Increase the Expression of PD-L1 in Ovarian Cancer
por: Cho, Min Soon, et al.
Publicado: (2022)

Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
por: Kim, Hae Su, et al.
Publicado: (2016)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma
por: Zhao, Ju, et al.
Publicado: (2022)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021)

Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
por: Okadome, Kazuo, et al.
Publicado: (2020)

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy
por: Shin, Kabsoo, et al.
Publicado: (2023)

The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer
por: Zhu, Xinxin, et al.
Publicado: (2018)

Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis
por: Xu, Jun, et al.
Publicado: (2021)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
por: Drakes, Maureen L., et al.
Publicado: (2018)

Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis
por: Zhao, Tiancheng, et al.
Publicado: (2017)

Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer
por: Dumitru, Adrian, et al.
Publicado: (2022)

Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis
por: Suszczyk, Dorota, et al.
Publicado: (2022)

Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma
por: Nie, Hanxiao, et al.
Publicado: (2021)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
por: Qin, Weiting, et al.
Publicado: (2019)

Prognostic value of TIM-1 expression in human non-small-cell lung cancer
por: Zheng, Xiao, et al.
Publicado: (2019)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
por: Ou, Shun-Long, et al.
Publicado: (2023)

Prognostic value of PD-L1 expression in patients with pancreatic cancer: A PRISMA-compliant meta-analysis
por: Hu, Ying, et al.
Publicado: (2019)

PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
por: Martin de la Fuente, Laura, et al.
Publicado: (2020)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
por: Rotman, Jossie, et al.
Publicado: (2020)

Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
por: Wang, Yusha, et al.
Publicado: (2022)

Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?
por: KORKMAZ, Serdal, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9vi9oivdrfmg9dv73hb4vvvf09